Axis Capital: ‘Buy’ on Biocon, target price stands at Rs 300

By: |
Published: September 20, 2019 3:12:37 AM

Investing for next growth cycle: Expects filing of bevacizumab in the US and the EU by end FY20 and approvals by FY22, Development of Insulin Aspart for EU and US, and developing a basket of biosimilars/NCEs in partnership and also under own label.

Biocon, target price, EBITDA, China market, india market, market news, biosimilar, Biocon recently entered into a licensing agreement with CMS for commercialisation of 3 small molecule generic formulations.

Biocon is well placed to monetise global Biosimilar opportunity with key launches from H2FY20: the management has highlighted its confidence on monetising opportunities from Trastuzumab launch in the US by Q3FY20, approval of insulin glargine in the US by March 20 and scaling-up in Peg-Filgrastim market share in the US from Q4FY20 given ongoing capacity expansion.

Investing for next growth cycle: Expects filing of bevacizumab in the US and the EU by end FY20 and approvals by FY22, Development of Insulin Aspart for EU and US, and developing a basket of biosimilars/NCEs in partnership and also under own label.

EBITDA margin expansion from FY21: Higher gross R&D and staff expenses (ramping up talent pool via global hires) would keep FY20 EBITDA margin under check, but improve from FY21 with scale-up in market share from Peg-Filgrastim, Trastuzumab and Glargine in the US.

Additional upside, unlocking biosimilars value via monetisation: Expects private equity infusion in biosimilar SPV in near term and later IPO in 12-24 months. China market entry: Biosimilars – given the recent Upjohn-Mylan merger, Biocon’s biosimilar molecules under Mylan partnership could get better access to the Chinese market given Upjohn’s strong foothold in China.

Biocon recently entered into a licensing agreement with CMS for commercialisation of 3 small molecule generic formulations.

Current correction (26% in 6 months) unwarranted as management remains confident of overcoming concerns on Peg-Filgrastim market share. Biocon is well positioned given strong earnings growth visibility (amid pharma sector volatility) on multi-product biosimilar portfolio and pipeline (own and partnered – Mylan, Sandoz) and NCE assets. ‘BUY’ with TP of Rs 300 (30x FY21E EPS).

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.